My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Exelixis, Inc. - Common Stock (NQ:EXEL)

42.14 -0.51 (-1.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗

December 17, 2024

Via Benzinga

NASDAQ:EXEL is showing decent growth, but is still valued reasonably. ↗

December 16, 2024

EXELIXIS INC (NASDAQ:EXEL) is showing good growth, while it is not too expensive.

Via Chartmill

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

2 Biotech Stocks to Buy Hand Over Fist in December ↗

December 07, 2024

Via The Motley Fool

End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis) ↗

December 01, 2024

As the calendar winds down, the stock market often heats up. This

Via Talk Markets

Topics Stocks / Equities

Earnings Preview: Exelixis ↗

October 28, 2024

Via Benzinga

1 No-Brainer Stock to Buy With $40 ↗

October 23, 2024

The midcap biotech just became an even better buy.

Via The Motley Fool

Analyst Ratings For Exelixis ↗

October 21, 2024

Via Benzinga

Navigating 16 Analyst Ratings For Exelixis ↗

October 21, 2024

Via Benzinga

Ten Young Ones ↗

November 30, 2024

Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays.

Via Talk Markets

Topics Stocks / Equities

NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗

November 29, 2024

EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December

November 27, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors

November 26, 2024

From Exelixis, Inc.

Via Business Wire

Key Takeaways From Exelixis Analyst Ratings ↗

October 04, 2024

Via Benzinga

BioNTech Stock Got A IBD RS Rating Lift ↗

November 14, 2024

A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance.

Via Investor's Business Daily

Vericel Stock Sees RS Rating Shoot Higher ↗

November 11, 2024

The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79.

Via Investor's Business Daily

NASDAQ:EXEL is an undervalued gem with solid fundamentals. ↗

November 08, 2024

For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals.

Via Chartmill

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November

November 07, 2024

From Exelixis, Inc.

Via Business Wire

3 Magnificent Stocks Under $100 to Buy in November ↗

November 03, 2024

The price could be right for these stocks.

Via The Motley Fool

Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗

November 03, 2024

The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts.

Via Benzinga

Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday ↗

October 30, 2024

Via Benzinga

Exelixis (EXEL) Q3 2024 Earnings Call Transcript ↗

October 30, 2024

EXEL earnings call for the period ending September 30, 2024.

Via The Motley Fool

Topics Earnings

Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update

October 29, 2024

From Exelixis, Inc.

Via Business Wire

Biotech Momentum Trades For The Q4 Rally ↗

October 29, 2024

The biotech sector made an interim peak in late February followed by an active summer in very choppy trading.

Via Talk Markets

Momentum Has Narrowed Again, Significantly ↗

October 28, 2024

It is more of a stock pickers market than usual as momentum factors are currently exaggerated.

Via Talk Markets

In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗

October 18, 2024

In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

October 15, 2024

From Exelixis, Inc.

Via Business Wire

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

October 14, 2024

From Exelixis, Inc.

Via Business Wire

Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas ↗

October 13, 2024

It is Fall clean up time. Sell lagging and sagging companies.

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.